Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis

Gynecologic Oncology

Volumn 139, Issue 2, 2015, Pages 355-362

  Li, Dong ^a,b   Ding, Cheng Yi ^c   Qiu, Li Hua ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Key Laboratory of Gynecologic Oncology   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Epithelial ovarian cancer; Hormone replacement therapy; Meta analysis; Overall survival; Recurrence

Indexed keywords

HORMONE;

CANCER GRADING; CANCER PATIENT; CANCER STAGING; DATA EXTRACTION; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; ESTROGEN THERAPY; MENOPAUSE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TUMOR RECURRENCE;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARIECTOMY; POSTOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84952630149     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.07.109     Document Type: Review

References (36)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J. Clin. 65 2015 5 29
2. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J. Clin. 61 2011 183 203
3. S.C. Plaxe, P.S. Braly, J.L. Freddo, E. McClay, S. Kirmani, and S.B. Howell Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer Obstet. Gynecol. 81 1993 651 654
4. M. Rodriguez, H.N. Nguyen, H.E. Averette, A.J. Steren, M.A. Penalver, T. Harrison, and B.U. Sevin National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age Cancer 73 1994 1245 1250
5. L.R. Duska, Y.C. Chang, C.E. Flynn, A.H. Chen, A. Goodman, A.F. Fuller, and N. Nikrui Epithelial ovarian carcinoma in the reproductive age group Cancer 85 1999 2623 2629
6. D.J. van Der Voort, P.H. van Der Weijer, and R. Barentsen Early menopause: increased fracture risk at older age Osteoporos. Int. 14 2003 525 530
7. R. Michaelson-Cohen, and U. Beller Managing menopausal symptoms after gynecological cancer Curr. Opin. Oncol. 21 2009 407 411
8. D. Vavilis, K. Chatzigeorgiou, D. Goulis, K. Pantazis, A. Papanicolaou, T.D. Theodoridis, and B.C. Tarlatzis Hormonal replacement therapy in ovarian cancer survivors: a survey among Greek gynecologists Eur. J. Gynaecol. Oncol. 32 2011 538 541
9. I. Biliatis, N. Thomakos, A. Rodolakis, N. Akrivos, D. Zacharakis, and A. Antsaklis Safety of hormone replacement therapy in gynaecological cancer survivors J. Obstet. Gynaecol. 32 2012 321 325
10. D. Moher, L. Shamseer, M. Clarke, D. Ghersi, A. Liberati, M. Petticrew, P. Shekelle, L.A. Stewart, and P.-P. Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement Syst. Rev. 4 2015 1
11. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J. Clin. Epidemiol. 62 2009 1006 1012
12. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and H.J. McQuay Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17 1996 1 12
13. G.A. Wells, B. Shea, D. O'Connell, J. Peterson, V. Welch, M. Losos, and P. Tugwell The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-randomised Studies in Meta-analysis http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (accessed 25 February 2015)
14. O. Aziz, V. Constantinides, P.P. Tekkis, T. Athanasiou, S. Purkayastha, P. Paraskeva, A.W. Darzi, and A.G. Heriot Laparoscopic versus open surgery for rectal cancer: a meta-analysis Ann. Surg. Oncol. 13 2006 413 424
15. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
16. M. Sydes, and J.H.R. Tierney Calculation Spreadsheet 2007 MRC Clinical Trials Unit London < http://www.biomedcentral.com/content/supplementary/1745-6215-8-16-S1.xls > [accessed 31 February 2015]
17. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat. Med. 21 2002 1539 1558
18. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
19. J.P.T. Higgins, and S. Green Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011] 2011 The Cochrane Collaboration
20. F. Song, A.J. Eastwood, S. Gilbody, L. Duley, and A.J. Sutton Publication and related biases Health Technol. Assess. 4 2000 1 115
21. R.A. Eeles, S. Tan, E. Wiltshaw, I. Fryatt, R.P. A'Hern, J.H. Shepherd, C.L. Harmer, P.R. Blake, and C.E. Chilvers Hormone replacement therapy and survival after surgery for ovarian cancer BMJ 302 1991 259 262
22. F. Guidozzi, and A. Daponte Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial Cancer 86 1999 1013 1018
23. M. Ursic-Vrscaj, S. Bebar, and M.P. Zakelj Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival Menopause 8 2001 70 75
24. C. Mascarenhas, M. Lambe, R. Bellocco, K. Bergfeldt, T. Riman, I. Persson, and E. Weiderpass Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival Int. J. Cancer 119 2006 2907 2915
25. L. Li, Z. Pan, K. Gao, W. Zhang, Y. Luo, Z. Yao, X. Liang, B. Tang, and Q.Q. Li Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy Oncol. Lett. 3 2012 244 249
26. Y. Wen, H. Huang, H. Huang, M. Wu, K. Shen, and L. Pan The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China Climacteric 16 2013 673 681
27. N.S. Weiss, D.R. Szekely, D.R. English, and A.I. Schweid Endometrial cancer in relation to patterns of menopausal estrogen use JAMA 242 1979 261 264
28. P.A. Fasching, A.B. Ekici, B.R. Adamietz, D.L. Wachter, A. Hein, C.M. Bayer, L. Haberle, C.R. Loehberg, S.M. Jud, K. Heusinger, M. Rubner, C. Rauh, and et al. Breast cancer risk - genes, environment and clinics Geburtshilfe Frauenheilkd. 71 2011 1056 1066
29. A. Hein, F.C. Thiel, C.M. Bayer, P.A. Fasching, L. Haberle, M.P. Lux, S.P. Renner, S.M. Jud, M.G. Schrauder, A. Muller, D. Wachter, J. Strehl, and et al. Hormone replacement therapy and prognosis in ovarian cancer patients Eur. J. Cancer Prev. 22 2013 52 58
30. S.P. Langdon, G.L. Hirst, E.P. Miller, R.A. Hawkins, A.L. Tesdale, J.F. Smyth, and W.R. Miller The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines J. Steroid Biochem. Mol. Biol. 50 1994 131 135
31. L.A. Laviolette, K.M. Hodgkinson, N. Minhas, C. Perez-Iratxeta, and B.C. Vanderhyden 17beta-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo Int. J. Cancer 135 2014 1072 1084
32. B. Zhou, Q. Sun, R. Cong, H. Gu, N. Tang, L. Yang, and B. Wang Hormone replacement therapy and ovarian cancer risk: a meta-analysis Gynecol. Oncol. 108 2008 641 651
33. C. Campagnoli, F. Clavel-Chapelon, R. Kaaks, C. Peris, and F. Berrino Progestins and progesterone in hormone replacement therapy and the risk of breast cancer J. Steroid Biochem. Mol. Biol. 96 2005 95 108
34. J.V. Lacey Jr., P.J. Mink, J.H. Lubin, M.E. Sherman, R. Troisi, P. Hartge, A. Schatzkin, and C. Schairer Menopausal hormone replacement therapy and risk of ovarian cancer JAMA 288 2002 334 341
35. L.G.K. Li, W. Zhang, and X. Chen Effects of estradiol and progesterone on ovarian cancer cell line Zhonghua Zhongliu Zazhi 25 2003 553 554
36. Y. Sun, Y. Wang, C. Fan, P. Gao, X. Wang, G. Wei, and J. Wei Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation Mol. Cancer 13 2014 137